FuelCell’s stock doubles in 4 days on increasing volume

Shares of FuelCell Energy Inc. FCEL, +23.78% soared 27.4% in very active afternoon trading Wednesday, putting them on track to more-than double in four days, despite no news released by the company. With the stock rallying 11.3% on Friday, soaring 31.4% on Monday and climbing 10.0% on Tuesday, it has now rocketed 105.1% during its current win streak. That’s the best four-day run for the fuel cell technology and power generation company’s stock since it tripled (up 205.4%) during the four days ended Dec. 31, 2019.

Glympse Bio clears first-in-human safety study of its injectable biosensors

Diagnosing nonalcoholic steatohepatitis (NASH)—the excessive buildup of fats in the liver that can lead to liver cancer, failure and the need for a transplant—has always been a difficult prospect. Tissue biopsies may hit the wrong spot and miss the diffuse signs entirely, while imaging methods can be limited in effectiveness and may be subjective.

OSE details novel immuno-oncology strategy targeting ‘don’t eat me’ signaling in cancer

One of the most sought-after targets in immuno-oncology over the past few years is “don’t eat me” signaling, a process by which tumors escape destruction by preventing immune cells from detecting, engulfing and destroying them. OSE Immunotherapeutics is among the companies pursuing this signaling pathway, and it has unveiled preclinical data supporting a novel strategy for disrupting it.

CymaBay tees up new phase 3 study for resurrected liver drug as truncated trial shows promise

CymaBay Therapeutics is getting its liver disease drug back on track. The treatment beat placebo at lowering a liver enzyme in patients with primary biliary cholangitis (PBC), a rare, progressive disease that can lead to inflammation and scarring in the liver. The data come one year after the company halted all clinical development of the drug, seladelpar, and four months after it resurrected the program.

error: Content is protected !!